Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risdiplam - PTC Therapeutics/Roche

Next Previous
Drug Profile

Risdiplam - PTC Therapeutics/Roche

Alternative Names: Evrysdi; EvrysdiTM; RG-7916; RO-7034067

Latest Information Update: 15 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PTC Therapeutics
  • Developer Chugai Pharmaceutical; PTC Therapeutics; Roche
  • Class 2 ring heterocyclic compounds; Imidazoles; Pyridazines; Pyrimidines; Small molecules; Spiro compounds
  • Mechanism of Action Survival of motor neuron 2 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal muscular atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Spinal muscular atrophy

Most Recent Events

  • 22 Dec 2023 Roche completes the phase II FIREFISH trial in Spinal muscular atrophy (In infants) in Belgium, France, Germany, Italy, Switzerland, Turkey, China, Croatia, Japan, Brazil, Poland, Russia, Serbia, Saudi Arabia, Spain and the US (PO) (NCT02913482) (JapicCTI183891) (EudraCT2016-000778-40)
  • 04 Oct 2023 Efficacy and adverse events data from a phase II RAINBOWFISH trial in Spinal muscular atrophy released by Roche
  • 02 Oct 2023 Hoffmann-La Roche completes the phase II SUNFISH trial in Spinal muscular atrophy (In adolescents, In children, In adults) in Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, England, France, Germany, Hungary, Italy, Japan, Mexico, Multinational, Netherlands, Poland, Romania, Russia, Serbia, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, and USA (PO) (NCT02908685) (EudraCT2016-000750-35)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top